Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Ozempic Price Gets Cut in Half for Cash Customers
Posted
August 18, 2025
Views
789
Likes
16
Comments
2
Engagement
2.28%
August 18, 2025
789
16
2
2.28%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
28:47
4:36Now PlayingBloomberg Health Reporter Madison Muller breaks down the latest news from Novo Nordisk, as the company halves Ozempic pricing for cash customers and gets US approval for Wegovy's treatment of liver disease.
Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices.
Patients can now get Ozempic for $499 a month — about half of its US list price — through Novo’s cash-pay pharmacy NovoCare, the company said in a statement Monday. It’s also partnering with GoodRx Holdings Inc. to offer Ozempic and its sister weight-loss drug Wegovy for the same price at pharmacies across the US.
President Donald Trump has been putting pressure on pharmaceutical companies to lower prices, including sending letters to drugmakers like Novo demanding action. The Biden administration previously attempted to get Novo to lower the price of Ozempic, the Danish company’s best-selling drug, without success.
Novo said the offer is unrelated to its discussions with the US government. It comes less than a week after weight-loss rival Eli Lilly & Co. made its own adjustment, raising the list price for its obesity shot in the UK by as much as 170%. Still, it’s not yet clear how much difference either measure will make when it comes to variations in what patients actually pay across countries.
Novo’s shares gained as much as 7.8% to a session high following the announcement. The stock was already advancing on Monday after Wegovy received Food and Drug Administration approval to treat a serious form of liver disease.
The news also sent GoodRx’s stock up 39%, its biggest intraday jump since September 2020. GoodRx Chief Executive Officer Wendy Barnes said the partnership with Novo makes it much easier for patients to get a more affordable version of the drugs.
“We are the number one branded marketplace to seek cash pricing on brands and generics, so for that reason we already have the millions of consumers searching for these types of products,” Barnes said in an interview with Bloomberg TV. “This is where they are looking for the most affordable price and the ability to access them.”
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
